ZA200104094B - Novel triazolo(4,5-d)pyrimidine compounds. - Google Patents
Novel triazolo(4,5-d)pyrimidine compounds. Download PDFInfo
- Publication number
- ZA200104094B ZA200104094B ZA200104094A ZA200104094A ZA200104094B ZA 200104094 B ZA200104094 B ZA 200104094B ZA 200104094 A ZA200104094 A ZA 200104094A ZA 200104094 A ZA200104094 A ZA 200104094A ZA 200104094 B ZA200104094 B ZA 200104094B
- Authority
- ZA
- South Africa
- Prior art keywords
- pyrimidin
- triazolo
- tetrahydro
- dimethyl
- cyclopenta
- Prior art date
Links
- 150000003230 pyrimidines Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims description 86
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N EtOH Substances CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 24
- 238000000034 method Methods 0.000 claims description 22
- -1 3,4- difluorophenyl Chemical group 0.000 claims description 21
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 21
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 20
- 150000003839 salts Chemical class 0.000 claims description 19
- 238000011282 treatment Methods 0.000 claims description 18
- 125000000217 alkyl group Chemical group 0.000 claims description 16
- 239000000203 mixture Substances 0.000 claims description 15
- 230000002265 prevention Effects 0.000 claims description 14
- 125000000446 sulfanediyl group Chemical group *S* 0.000 claims description 14
- 125000006239 protecting group Chemical group 0.000 claims description 12
- 239000012453 solvate Substances 0.000 claims description 12
- 239000000126 substance Substances 0.000 claims description 11
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 10
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 10
- 230000008569 process Effects 0.000 claims description 10
- 125000001153 fluoro group Chemical group F* 0.000 claims description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Substances OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 9
- 206010002388 Angina unstable Diseases 0.000 claims description 8
- 208000007814 Unstable Angina Diseases 0.000 claims description 8
- 201000004332 intermediate coronary syndrome Diseases 0.000 claims description 8
- 208000010125 myocardial infarction Diseases 0.000 claims description 7
- 208000018262 Peripheral vascular disease Diseases 0.000 claims description 6
- 206010043647 Thrombotic Stroke Diseases 0.000 claims description 6
- 239000002253 acid Substances 0.000 claims description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 6
- 125000000524 functional group Chemical group 0.000 claims description 6
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 6
- 208000010110 spontaneous platelet aggregation Diseases 0.000 claims description 6
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims description 5
- 208000007718 Stable Angina Diseases 0.000 claims description 5
- 208000032109 Transient ischaemic attack Diseases 0.000 claims description 5
- 208000035475 disorder Diseases 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 5
- 239000012442 inert solvent Substances 0.000 claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 4
- 229910052731 fluorine Inorganic materials 0.000 claims description 4
- 239000011737 fluorine Substances 0.000 claims description 4
- 125000005843 halogen group Chemical group 0.000 claims description 4
- 239000004480 active ingredient Substances 0.000 claims description 3
- 229910052739 hydrogen Inorganic materials 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- 238000002560 therapeutic procedure Methods 0.000 claims description 3
- 125000001847 2-phenylcyclopropyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C1([H])C([H])([H])C1([H])* 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 claims description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims 3
- 150000004702 methyl esters Chemical class 0.000 claims 2
- YOYMEMZJDPJGNY-UHFFFAOYSA-N 2-butylsulfanyl-4,6-dichloropyrimidin-5-amine Chemical compound CCCCSC1=NC(Cl)=C(N)C(Cl)=N1 YOYMEMZJDPJGNY-UHFFFAOYSA-N 0.000 claims 1
- CWFSKWMXGJLZBE-UHFFFAOYSA-N 6ah-cyclopenta[d][1,3]dioxol-6-ol Chemical compound O1COC2C(O)=CC=C21 CWFSKWMXGJLZBE-UHFFFAOYSA-N 0.000 claims 1
- VCVOSERVUCJNPR-UHFFFAOYSA-N cyclopentane-1,2-diol Chemical compound OC1CCCC1O VCVOSERVUCJNPR-UHFFFAOYSA-N 0.000 claims 1
- 125000004212 difluorophenyl group Chemical group 0.000 claims 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 1
- 230000000302 ischemic effect Effects 0.000 claims 1
- KXKVLQRXCPHEJC-UHFFFAOYSA-N methyl acetate Chemical compound COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 claims 1
- 230000001052 transient effect Effects 0.000 claims 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 10
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 10
- 239000002904 solvent Substances 0.000 description 10
- XTWYTFMLZFPYCI-KQYNXXCUSA-N 5'-adenylphosphoric acid Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XTWYTFMLZFPYCI-KQYNXXCUSA-N 0.000 description 8
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 8
- 239000003146 anticoagulant agent Substances 0.000 description 8
- 239000002585 base Substances 0.000 description 8
- 239000000843 powder Substances 0.000 description 7
- 230000009467 reduction Effects 0.000 description 7
- 230000001732 thrombotic effect Effects 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 5
- 230000002776 aggregation Effects 0.000 description 5
- 238000004220 aggregation Methods 0.000 description 5
- 238000010511 deprotection reaction Methods 0.000 description 5
- 229910052757 nitrogen Inorganic materials 0.000 description 5
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 5
- 150000001412 amines Chemical class 0.000 description 4
- 239000005557 antagonist Substances 0.000 description 4
- 230000000702 anti-platelet effect Effects 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000029936 alkylation Effects 0.000 description 3
- 238000005804 alkylation reaction Methods 0.000 description 3
- 229960004676 antithrombotic agent Drugs 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 239000003054 catalyst Substances 0.000 description 3
- 230000004087 circulation Effects 0.000 description 3
- 150000002148 esters Chemical group 0.000 description 3
- 229910052736 halogen Inorganic materials 0.000 description 3
- 150000002367 halogens Chemical class 0.000 description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- 230000010118 platelet activation Effects 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 229910052723 transition metal Inorganic materials 0.000 description 3
- 150000003624 transition metals Chemical class 0.000 description 3
- 230000002792 vascular Effects 0.000 description 3
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- GIIGHSIIKVOWKZ-UHFFFAOYSA-N 2h-triazolo[4,5-d]pyrimidine Chemical class N1=CN=CC2=NNN=C21 GIIGHSIIKVOWKZ-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 102100025306 Integrin alpha-IIb Human genes 0.000 description 2
- 101710149643 Integrin alpha-IIb Proteins 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 2
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- 108090000190 Thrombin Proteins 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- 206010047249 Venous thrombosis Diseases 0.000 description 2
- 229960001138 acetylsalicylic acid Drugs 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 239000000908 ammonium hydroxide Substances 0.000 description 2
- 238000002399 angioplasty Methods 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- 150000001540 azides Chemical class 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- ILAHWRKJUDSMFH-UHFFFAOYSA-N boron tribromide Chemical compound BrB(Br)Br ILAHWRKJUDSMFH-UHFFFAOYSA-N 0.000 description 2
- 229940112141 dry powder inhaler Drugs 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 2
- 238000005984 hydrogenation reaction Methods 0.000 description 2
- 230000033444 hydroxylation Effects 0.000 description 2
- 238000005805 hydroxylation reaction Methods 0.000 description 2
- OWFXIOWLTKNBAP-UHFFFAOYSA-N isoamyl nitrite Chemical compound CC(C)CCON=O OWFXIOWLTKNBAP-UHFFFAOYSA-N 0.000 description 2
- 125000000654 isopropylidene group Chemical group C(C)(C)=* 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 229910052763 palladium Inorganic materials 0.000 description 2
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- HJUGFYREWKUQJT-UHFFFAOYSA-N tetrabromomethane Chemical compound BrC(Br)(Br)Br HJUGFYREWKUQJT-UHFFFAOYSA-N 0.000 description 2
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 2
- 229960004072 thrombin Drugs 0.000 description 2
- 230000002537 thrombolytic effect Effects 0.000 description 2
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- YQKSRXKUVVMWPH-UHFFFAOYSA-N 1-(hydroxymethyl)cyclopentane-1,2-diol Chemical compound OCC1(O)CCCC1O YQKSRXKUVVMWPH-UHFFFAOYSA-N 0.000 description 1
- KKJUPNGICOCCDW-UHFFFAOYSA-N 7-N,N-Dimethylamino-1,2,3,4,5-pentathiocyclooctane Chemical compound CN(C)C1CSSSSSC1 KKJUPNGICOCCDW-UHFFFAOYSA-N 0.000 description 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 208000003343 Antiphospholipid Syndrome Diseases 0.000 description 1
- 206010003178 Arterial thrombosis Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 206010051055 Deep vein thrombosis Diseases 0.000 description 1
- 241001459693 Dipterocarpus zeylanicus Species 0.000 description 1
- 206010014498 Embolic stroke Diseases 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 1
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 208000032759 Hemolytic-Uremic Syndrome Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 102000007625 Hirudins Human genes 0.000 description 1
- 108010007267 Hirudins Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 239000012448 Lithium borohydride Substances 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 208000014767 Myeloproliferative disease Diseases 0.000 description 1
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-diisopropylethylamine Substances CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- 206010037549 Purpura Diseases 0.000 description 1
- 241001672981 Purpura Species 0.000 description 1
- 208000012322 Raynaud phenomenon Diseases 0.000 description 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 206010040621 Shunt occlusion Diseases 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 229940122388 Thrombin inhibitor Drugs 0.000 description 1
- 208000005485 Thrombocytosis Diseases 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- 206010047115 Vasculitis Diseases 0.000 description 1
- 208000012346 Venoocclusive disease Diseases 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 238000005903 acid hydrolysis reaction Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 description 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 1
- 229910000272 alkali metal oxide Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910001860 alkaline earth metal hydroxide Inorganic materials 0.000 description 1
- 125000001118 alkylidene group Chemical group 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 229940127090 anticoagulant agent Drugs 0.000 description 1
- 229940127218 antiplatelet drug Drugs 0.000 description 1
- 239000011260 aqueous acid Substances 0.000 description 1
- 206010003230 arteritis Diseases 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000003143 atherosclerotic effect Effects 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- HSDAJNMJOMSNEV-UHFFFAOYSA-N benzyl chloroformate Chemical compound ClC(=O)OCC1=CC=CC=C1 HSDAJNMJOMSNEV-UHFFFAOYSA-N 0.000 description 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
- 239000010836 blood and blood product Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 229940125691 blood product Drugs 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 230000002612 cardiopulmonary effect Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 208000015114 central nervous system disease Diseases 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 238000007887 coronary angioplasty Methods 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- MVHTVXFDPMHZNE-UHFFFAOYSA-N cyclopentane-1,2,3-triol Chemical compound OC1CCC(O)C1O MVHTVXFDPMHZNE-UHFFFAOYSA-N 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000009190 disseminated intravascular coagulation Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000013171 endarterectomy Methods 0.000 description 1
- DQYBDCGIPTYXML-UHFFFAOYSA-N ethoxyethane;hydrate Chemical compound O.CCOCC DQYBDCGIPTYXML-UHFFFAOYSA-N 0.000 description 1
- 125000003720 ethoxymethylidene group Chemical group [H]C(=*)OC([H])([H])C([H])([H])[H] 0.000 description 1
- PQJJJMRNHATNKG-UHFFFAOYSA-N ethyl bromoacetate Chemical compound CCOC(=O)CBr PQJJJMRNHATNKG-UHFFFAOYSA-N 0.000 description 1
- 238000002618 extracorporeal membrane oxygenation Methods 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000002140 halogenating effect Effects 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- WQPDUTSPKFMPDP-OUMQNGNKSA-N hirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(OS(O)(=O)=O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@H](C(NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N2)=O)CSSC1)C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)CSSC1)C(C)C)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 WQPDUTSPKFMPDP-OUMQNGNKSA-N 0.000 description 1
- 229940006607 hirudin Drugs 0.000 description 1
- 229910000040 hydrogen fluoride Inorganic materials 0.000 description 1
- 238000007327 hydrogenolysis reaction Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 150000003951 lactams Chemical class 0.000 description 1
- 239000012280 lithium aluminium hydride Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229910052987 metal hydride Inorganic materials 0.000 description 1
- 150000004681 metal hydrides Chemical class 0.000 description 1
- 229910000000 metal hydroxide Inorganic materials 0.000 description 1
- 150000004692 metal hydroxides Chemical class 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000000269 nucleophilic effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 229910000489 osmium tetroxide Inorganic materials 0.000 description 1
- 239000012285 osmium tetroxide Substances 0.000 description 1
- 229940019331 other antithrombotic agent in atc Drugs 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 239000003182 parenteral nutrition solution Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- IDOWTHOLJBTAFI-UHFFFAOYSA-N phenmedipham Chemical compound COC(=O)NC1=CC=CC(OC(=O)NC=2C=C(C)C=CC=2)=C1 IDOWTHOLJBTAFI-UHFFFAOYSA-N 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 230000007505 plaque formation Effects 0.000 description 1
- 238000002616 plasmapheresis Methods 0.000 description 1
- 239000000106 platelet aggregation inhibitor Substances 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
- 201000011461 pre-eclampsia Diseases 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 125000001453 quaternary ammonium group Chemical group 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 238000002278 reconstructive surgery Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 208000037803 restenosis Diseases 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 208000007056 sickle cell anemia Diseases 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- 235000010288 sodium nitrite Nutrition 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 230000036262 stenosis Effects 0.000 description 1
- 208000037804 stenosis Diseases 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000001117 sulphuric acid Substances 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- XCAQIUOFDMREBA-UHFFFAOYSA-N tert-butyl n-[(2-methylpropan-2-yl)oxycarbonyl]carbamate Chemical compound CC(C)(C)OC(=O)NC(=O)OC(C)(C)C XCAQIUOFDMREBA-UHFFFAOYSA-N 0.000 description 1
- ILMRJRBKQSSXGY-UHFFFAOYSA-N tert-butyl(dimethyl)silicon Chemical group C[Si](C)C(C)(C)C ILMRJRBKQSSXGY-UHFFFAOYSA-N 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 239000003868 thrombin inhibitor Substances 0.000 description 1
- 239000003634 thrombocyte concentrate Substances 0.000 description 1
- 206010043554 thrombocytopenia Diseases 0.000 description 1
- 208000014754 thrombocytosis disease Diseases 0.000 description 1
- RZWIIPASKMUIAC-VQTJNVASSA-N thromboxane Chemical compound CCCCCCCC[C@H]1OCCC[C@@H]1CCCCCCC RZWIIPASKMUIAC-VQTJNVASSA-N 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 125000004665 trialkylsilyl group Chemical group 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
- 230000003966 vascular damage Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C211/00—Compounds containing amino groups bound to a carbon skeleton
- C07C211/33—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings
- C07C211/39—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton
- C07C211/40—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton containing only non-condensed rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Vascular Medicine (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE9804211A SE9804211D0 (sv) | 1998-12-04 | 1998-12-04 | Novel compounds |
| SE9901271A SE9901271D0 (sv) | 1999-04-09 | 1999-04-09 | Novel compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200104094B true ZA200104094B (en) | 2002-08-19 |
Family
ID=26663448
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200104094A ZA200104094B (en) | 1998-12-04 | 2001-05-18 | Novel triazolo(4,5-d)pyrimidine compounds. |
Country Status (36)
| Country | Link |
|---|---|
| US (12) | US6525060B1 (pt) |
| EP (5) | EP1386917B1 (pt) |
| JP (4) | JP4202607B2 (pt) |
| KR (4) | KR100776484B1 (pt) |
| CN (1) | CN1128801C (pt) |
| AR (3) | AR023920A1 (pt) |
| AT (3) | ATE513816T1 (pt) |
| AU (1) | AU766618B2 (pt) |
| BR (1) | BRPI9915883B8 (pt) |
| CA (1) | CA2351709C (pt) |
| CY (3) | CY1110501T1 (pt) |
| CZ (3) | CZ295234B6 (pt) |
| DE (4) | DE69915675D1 (pt) |
| DK (3) | DK1386917T3 (pt) |
| EG (1) | EG24814A (pt) |
| ES (3) | ES2366902T3 (pt) |
| FR (1) | FR11C0016I2 (pt) |
| HK (3) | HK1061246A1 (pt) |
| HU (2) | HU228589B1 (pt) |
| ID (1) | ID29927A (pt) |
| IL (6) | IL143232A0 (pt) |
| LT (1) | LTC1135391I2 (pt) |
| LU (1) | LU91819I2 (pt) |
| MY (1) | MY121867A (pt) |
| NO (3) | NO319806B1 (pt) |
| NZ (1) | NZ511778A (pt) |
| PL (1) | PL201283B1 (pt) |
| PT (2) | PT1386921E (pt) |
| RU (3) | RU2317990C2 (pt) |
| SA (1) | SA99200848B1 (pt) |
| SI (3) | SI1386921T1 (pt) |
| SK (1) | SK286007B6 (pt) |
| TR (1) | TR200101567T2 (pt) |
| TW (1) | TWI229674B (pt) |
| WO (1) | WO2000034283A1 (pt) |
| ZA (1) | ZA200104094B (pt) |
Families Citing this family (124)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI229674B (en) | 1998-12-04 | 2005-03-21 | Astra Pharma Prod | Novel triazolo[4,5-d]pyrimidine compounds, pharmaceutical composition containing the same, their process for preparation and uses |
| SE9903290D0 (sv) * | 1999-09-15 | 1999-09-15 | Astra Pharma Prod | Novel compounds |
| SE9904129D0 (sv) | 1999-11-15 | 1999-11-15 | Astra Pharma Prod | Novel compounds |
| SE9904377D0 (sv) * | 1999-12-01 | 1999-12-01 | Astra Pharma Prod | Pharmaceutical combinations |
| TWI290549B (en) * | 2000-06-02 | 2007-12-01 | Astrazeneca Ab | Process for the preparation of cyclopropyl carboxylic acid ester and derivatives |
| GB0013407D0 (en) * | 2000-06-02 | 2000-07-26 | Astrazeneca Ab | Forms of a chemical compound |
| GB0013488D0 (en) * | 2000-06-02 | 2000-07-26 | Astrazeneca Ab | Chemical compound |
| US7452870B2 (en) | 2000-08-21 | 2008-11-18 | Inspire Pharmaceuticals, Inc. | Drug-eluting stents coated with P2Y12 receptor antagonist compound |
| US7115585B2 (en) | 2000-08-21 | 2006-10-03 | Inspire Pharmaceuticals, Inc. | Compositions for treating epithelial and retinal tissue diseases |
| US7018985B1 (en) | 2000-08-21 | 2006-03-28 | Inspire Pharmaceuticals, Inc. | Composition and method for inhibiting platelet aggregation |
| US6897201B2 (en) | 2000-08-21 | 2005-05-24 | Inspire Pharmaceuticals, Inc. | Compositions and methods for the treatment of glaucoma or ocular hypertension |
| US7132408B2 (en) | 2000-08-21 | 2006-11-07 | Inspire Pharmaceuticals, Inc. | Composition and method for inhibiting platelet aggregation |
| SE0101932D0 (sv) * | 2001-05-31 | 2001-05-31 | Astrazeneca Ab | Pharmaceutical combinations |
| US7435724B2 (en) | 2002-02-27 | 2008-10-14 | Inspire Pharmaceutical, Inc. | Degradation-resistant mononucleoside phosphate compounds |
| CN100471842C (zh) | 2003-07-24 | 2009-03-25 | 安斯泰来制药有限公司 | 喹诺酮衍生物或其盐 |
| SE0401001D0 (sv) | 2004-03-31 | 2004-03-31 | Astrazeneca Ab | Chemical process |
| SE0400873D0 (sv) | 2004-03-31 | 2004-03-31 | Astrazeneca Ab | Chemical process |
| JPWO2007020935A1 (ja) * | 2005-08-17 | 2009-02-26 | 小野薬品工業株式会社 | Ｐ２ｙ１２受容体および／またはｐ２ｙ１４受容体ブロッカーを含有してなる疼痛治療剤 |
| TWI391378B (zh) | 2006-03-16 | 2013-04-01 | Astellas Pharma Inc | 喹啉酮衍生物或其製藥學上可被容許之鹽 |
| GB0615620D0 (en) | 2006-08-05 | 2006-09-13 | Astrazeneca Ab | A process for the preparation of optically active intermediates |
| WO2008024044A1 (en) * | 2006-08-21 | 2008-02-28 | Astrazeneca Ab | Compositions, suitable for oral administration, comprising a triazolo [4, 5] pyrimidin derivate |
| TWI482772B (zh) * | 2006-08-21 | 2015-05-01 | Astrazeneca Ab | 適合口服且包含三唑并[4,5-d]嘧啶衍生物之組合物 |
| JP2010508350A (ja) | 2006-10-31 | 2010-03-18 | ヤンセン ファーマシューティカ エヌ．ベー． | Ａｄｐｐ２ｙ１２レセプターアンタゴニストとしてのトリアゾロピリミジン誘導体 |
| TWI496776B (zh) * | 2007-11-15 | 2015-08-21 | Astrazeneca Ab | 製備(3aR,4S,6R,6aS)-6-胺基-2,2-二甲基四氫-3aH-環戊并[d][1,3]二氧雜環戊烯-4-醇之純非對映異構性之二苯甲醯-L-酒石酸鹽之方法 |
| UA100864C2 (uk) * | 2007-12-03 | 2013-02-11 | Астразенека Аб | Спосіб лікування або запобігання аневризмі черевної аорти |
| TWI389913B (zh) * | 2008-09-08 | 2013-03-21 | Lg Life Sciences Ltd | 并合雜環化合物 |
| US8563755B2 (en) | 2008-09-09 | 2013-10-22 | Astrazeneca Ab | Process for preparing [1S-[1-α, 2-α, 3-β(1S*,2R*) 5-β]]-3-[7-[2-(3,4-difluorophenyl)-cyclopropylamino]-5-(propylthio)-3H-1,2,3-triazolo [4,5-d] pyrimidin-3-yl]-5-(2-hydroxyethoxy) cyclopentane-1,2-diol and to its intermediates |
| WO2010043721A1 (en) | 2008-10-17 | 2010-04-22 | Oryzon Genomics, S.A. | Oxidase inhibitors and their use |
| EP2389362B1 (en) | 2009-01-21 | 2019-12-11 | Oryzon Genomics, S.A. | Phenylcyclopropylamine derivatives and their medical use |
| WO2011017108A2 (en) * | 2009-07-27 | 2011-02-10 | Auspex Pharmaceuticals, Inc. | Cyclopropyl modulators of p2y12 receptor |
| EP2305376A1 (en) | 2009-09-23 | 2011-04-06 | Lonza Ltd. | Process and catalyst for the catalytic hydrogenation of aromatic and heteroaromatic nitro compounds |
| KR101736218B1 (ko) | 2009-09-25 | 2017-05-16 | 오리존 지노믹스 에스.에이. | 라이신 특이적 디메틸라아제-1 억제제 및 이의 용도 |
| EP2486002B1 (en) | 2009-10-09 | 2019-03-27 | Oryzon Genomics, S.A. | Substituted heteroaryl- and aryl- cyclopropylamine acetamides and their use |
| WO2011067571A1 (en) | 2009-12-03 | 2011-06-09 | Astrazeneca Ab | Co - crystals of a triazolo [4,5 - d] pyrimidine platelet aggregation inhibitor |
| ES2550033T3 (es) | 2009-12-23 | 2015-11-04 | Ratiopharm Gmbh | Forma de dosificación farmacéutica sólida de ticagrelor |
| US8859769B2 (en) | 2010-02-16 | 2014-10-14 | Actavis Group Ptc Ehf | Processes for preparing ticagrelor intermediate, 4,6-dichloro-5-nitro-2-(propylthio)pyrimidine |
| WO2011106573A2 (en) | 2010-02-24 | 2011-09-01 | Oryzon Genomics, S.A. | Lysine demethylase inhibitors for diseases and disorders associated with hepadnaviridae |
| WO2011106105A2 (en) | 2010-02-24 | 2011-09-01 | Oryzon Genomics, S.A. | Inhibitors for antiviral use |
| ES2607081T3 (es) | 2010-04-19 | 2017-03-29 | Oryzon Genomics, S.A. | Inhibidores de desmetilasa específica de lisina-1 y su uso |
| US20130150577A1 (en) | 2010-04-20 | 2013-06-13 | Actavis Group Ptc Ehf | Novel process for preparing phenylcyclopropylamine derivatives using novel intermediates |
| CN103003231A (zh) | 2010-06-30 | 2013-03-27 | 阿特维斯集团公司 | 制备苯基环丙基胺衍生物的新方法及其用于制备替卡格雷的用途 |
| HUE037937T2 (hu) | 2010-07-29 | 2021-11-29 | Oryzon Genomics Sa | Arilciklopropilamin-alapú LSD1-demetiláz inhibitorok és gyógyászati alkalmazásuk |
| US9006449B2 (en) | 2010-07-29 | 2015-04-14 | Oryzon Genomics, S.A. | Cyclopropylamine derivatives useful as LSD1 inhibitors |
| US9061966B2 (en) | 2010-10-08 | 2015-06-23 | Oryzon Genomics S.A. | Cyclopropylamine inhibitors of oxidases |
| WO2012063126A2 (en) | 2010-11-09 | 2012-05-18 | Actavis Group Ptc Ehf | Improved processes for preparing pure (3ar,4s,6r,6as)-6-amino-2,2-dimethyltetrahdro-3ah-cyclopenta[d] [1,3]-dioxol-4-ol and its key starting material |
| WO2012072713A2 (en) | 2010-11-30 | 2012-06-07 | Oryzon Genomics, S.A. | Lysine demethylase inhibitors for diseases and disorders associated with flaviviridae |
| RU2013133879A (ru) * | 2010-12-20 | 2015-01-27 | Актавис Груп Птс Ехф | НОВЫЕ СПОСОБЫ ПОЛУЧЕНИЯ ТРИАЗОЛО[4, 5-d]ПИРИМИДИНА, ЕГО ПРОИЗВОДНЫЕ И ПРОМЕЖУТОЧНЫЕ СОЕДИНЕНИЯ |
| WO2012107498A1 (en) | 2011-02-08 | 2012-08-16 | Oryzon Genomics S.A. | Lysine demethylase inhibitors for myeloproliferative disorders |
| CN102653539B (zh) * | 2011-03-01 | 2014-09-17 | 秦引林 | 一种抗血小板聚集化合物及其药物组合 |
| CA2832570A1 (en) | 2011-04-06 | 2012-10-11 | Teva Pharmaceutical Industries Ltd. | New intermediates and processes for preparing ticagrelor |
| CN102731510B (zh) * | 2011-04-07 | 2015-12-16 | 博瑞生物医药（苏州）股份有限公司 | 替卡格雷的衍生物、制备方法及其药物用途 |
| CZ2011229A3 (cs) * | 2011-04-19 | 2012-08-15 | Zentiva, K.S. | Opticky aktivní soli (3aR,4S,6R,6aS)-6-amino-2,2-dimethyltetrahydro-3aH-cyklopenta-[d][1,3]dioxol-4-olu a zpusob jejich prípravy |
| MX2013013221A (es) | 2011-05-13 | 2013-12-02 | Astrazeneca Ab | Proceso para la preparacion de [(3as, 4r, 6s, 6ar) -6- hidroxi-2, 2-dimetiltetrahidro-3ah-ciclopenta [d] [1, 3] dioxol-4-il] carbamato de bencilo e intermedios del proceso. |
| EP2741741A2 (en) * | 2011-05-19 | 2014-06-18 | Oryzon Genomics, S.A. | Lysine demethylase inhibitors for inflammatory diseases or conditions |
| US20140296255A1 (en) * | 2011-05-19 | 2014-10-02 | Oryzong Genomics, S.A. | Lysine demethylase inhibitors for thrombosis and cardiovascular diseases |
| CA2836394A1 (en) | 2011-06-01 | 2012-12-06 | Astrazeneca Ab | Novel ticagrelor co - crystal |
| CA2839057A1 (en) | 2011-06-15 | 2012-12-20 | Actavis Group Ptc Ehf | Improved process for preparing cyclopentylamine derivatives and intermediates thereof |
| CN102924457A (zh) * | 2011-08-12 | 2013-02-13 | 上海恒瑞医药有限公司 | 三唑并嘧啶类衍生物、其制备方法及其用途 |
| EP2570405A1 (en) | 2011-09-14 | 2013-03-20 | LEK Pharmaceuticals d.d. | Synthesis of Triazolopyrimidine Compounds |
| HUE031673T2 (en) | 2011-09-14 | 2017-07-28 | Lek Pharmaceuticals | Synthesis of triazolopyrimidine compounds |
| PE20141692A1 (es) | 2011-10-20 | 2014-11-08 | Oryzon Genomics Sa | Compuestos de (hetero) aril ciclopropilamina como inhibidores de lsd1 |
| EP2768805B1 (en) | 2011-10-20 | 2020-03-25 | Oryzon Genomics, S.A. | (hetero)aryl cyclopropylamine compounds as lsd1 inhibitors |
| CA2852652A1 (en) | 2011-10-27 | 2013-05-02 | Lek Pharmaceuticals D.D. | Synthesis of triazolopyrimidine compounds |
| EP2586773A1 (en) | 2011-10-27 | 2013-05-01 | LEK Pharmaceuticals d.d. | Synthesis of Triazolopyrimidine Compounds |
| EP2589587A1 (en) | 2011-11-04 | 2013-05-08 | Chemo Ibérica, S.A. | Synthesis of nitrogen substituted cyclopropanes |
| MX2014006190A (es) | 2011-11-30 | 2014-07-10 | Actavis Group Ptc Ehf | Nueva forma cristalina de ticagrelor y proceso para la preparacion de la misma. |
| EP2607355A1 (en) * | 2011-12-23 | 2013-06-26 | LEK Pharmaceuticals d.d. | Synthesis of triazolopyrimidine compounds |
| US9278972B2 (en) | 2011-12-23 | 2016-03-08 | Lek Pharmaceuticals D.D. | Synthesis of triazolopyrimidine compounds |
| EP2628721A1 (en) | 2012-02-20 | 2013-08-21 | LEK Pharmaceuticals d.d. | Synthesis of 2-(3,4-difluorophenyl)cyclopropanecarboxylic acid |
| EP2644590A1 (en) | 2012-03-30 | 2013-10-02 | LEK Pharmaceuticals d.d. | Synthesis of 2-(3,4-difluorophenyl)cyclopropanamine derivatives and salts |
| CN104603098B (zh) | 2012-03-30 | 2016-06-29 | 桑多斯股份公司 | 2-(3,4-二氟苯基)环丙胺衍生物和盐的合成 |
| EP2834247A4 (en) | 2012-04-05 | 2016-03-30 | Reddys Lab Ltd Dr | PREPARATION OF TICAGRELOR |
| WO2013163892A1 (en) * | 2012-05-02 | 2013-11-07 | Sunshine Lake Pharma Co., Ltd. | Novel triazolo pyrimidine compounds and a process of preparation thereof |
| CN102659815B (zh) * | 2012-05-04 | 2013-07-17 | 开原亨泰制药股份有限公司 | 一种制备选择性抗凝血药替卡格雷及其中间体的方法 |
| EP2666771A1 (en) | 2012-05-24 | 2013-11-27 | LEK Pharmaceuticals d.d. | Synthesis of Aminocyclopentanetriol Derivatives |
| ITMI20121142A1 (it) * | 2012-06-28 | 2013-12-29 | Chemo Iberica Sa | Processo chemoenzimatico per la produzione di fenil ciclopropilammine |
| WO2014000719A1 (en) | 2012-06-29 | 2014-01-03 | Zentiva, K.S. | Novel pharmaceutical solid forms of (1s,2s,3r,5s)-3-[7-[(1r,2s)-2-(3,4difluorophenyl)cyclopropylamino]-5-(propylthio)-3h-[1,2,3]triazolo[4,5-d]pyrimidin-3yl]-5-(2-hydroxyethoxy)cyclopentane-l,2-diol |
| CN104640864B (zh) * | 2012-07-04 | 2016-11-16 | 力奇制药公司 | 替格瑞洛与二价金属盐的加合物 |
| CN103626743B (zh) * | 2012-08-23 | 2018-06-08 | 广东东阳光药业有限公司 | 替卡格雷的新型中间体及其制备方法 |
| CN102875537A (zh) * | 2012-09-10 | 2013-01-16 | 常州制药厂有限公司 | 一种新的抗血栓药物的制备方法 |
| CZ2012705A3 (cs) | 2012-10-16 | 2014-04-23 | Zentiva, K.S. | Pevná orální farmaceutická formulace obsahující ticagrelor |
| WO2014083139A1 (en) | 2012-11-29 | 2014-06-05 | Actavis Group Ptc Ehf | Novel amorphous form of ticagrelor |
| WO2014102830A1 (en) | 2012-12-31 | 2014-07-03 | Megafine Pharma (P) Ltd. | A process for preparation of ticagrelor and intermediates thereof |
| CN104045620B (zh) * | 2013-03-12 | 2017-05-10 | 博瑞生物医药（苏州）股份有限公司 | 一种替卡格雷中间体的制备方法 |
| CZ307217B6 (cs) | 2013-03-14 | 2018-04-04 | Zentiva, K.S. | Zlepšený způsob výroby a nové intermediáty syntézy ticagreloru |
| IN2013MU01111A (pt) * | 2013-03-25 | 2015-05-01 | Glenmark Generics Ltd | |
| ITMI20130487A1 (it) | 2013-03-29 | 2014-09-30 | Chemo Res S L | Alchilazione selettiva di ciclopentilalcoli |
| CN107573333B (zh) | 2013-04-10 | 2019-10-18 | 江苏恒瑞医药股份有限公司 | 替格瑞洛的中间体及其制备方法和替格瑞洛的制备方法 |
| WO2014170026A1 (en) | 2013-04-18 | 2014-10-23 | Zentiva, K.S. | Stabilized amorphous ticagrelor |
| EP2813216A1 (en) | 2013-06-10 | 2014-12-17 | Zentiva, a.s. | Stabilized amorphous ticagrelor |
| CN104230818B (zh) * | 2013-06-06 | 2018-01-12 | 郝聪梅 | 替卡格雷中间体的改进制备方法 |
| EP2816043A1 (en) | 2013-06-21 | 2014-12-24 | LEK Pharmaceuticals d.d. | Spherical ticagrelor particles |
| WO2014206187A1 (zh) | 2013-06-24 | 2014-12-31 | 苏州明锐医药科技有限公司 | 替卡格雷及其中间体的制备方法 |
| CN104250251B (zh) * | 2013-06-25 | 2017-05-17 | 上海京新生物医药有限公司 | 一种替格瑞洛的制备方法 |
| WO2015001489A1 (en) | 2013-07-01 | 2015-01-08 | Ranbaxy Laboratories Limited | Pharmaceutical compositions of ticagrelor |
| CZ2013866A3 (cs) | 2013-11-08 | 2015-05-20 | Zentiva, K.S. | Způsob výroby a nová krystalická forma intermediátu syntézy ticagreloru |
| WO2015110952A1 (en) | 2014-01-21 | 2015-07-30 | Wockhardt Limited | Solid oral pharmaceutical compositions comprising ticagrelor or salt thereof |
| CN103992323B (zh) * | 2014-04-18 | 2017-03-29 | 南通常佑药业科技有限公司 | 一种替格瑞洛的制备方法 |
| WO2015162630A1 (en) | 2014-04-25 | 2015-10-29 | Anlon Chemical Research Organization | Novel processes for preparing triazolo [4,5-d]- pyrimidines, including ticagrelor, vianew intermediates and new route of synthesis. |
| DE102014108210A1 (de) | 2014-06-11 | 2015-12-17 | Dietrich Gulba | Rodentizid |
| EP3157907B1 (en) | 2014-06-18 | 2018-08-29 | Flamma S.P.A. | Process for the preparation of triazolo[4,5-d]pyrimidine cyclopentane compounds |
| CN105272985B (zh) * | 2014-06-24 | 2017-11-21 | 珠海联邦制药股份有限公司 | 三唑并[4,5‑d]嘧啶化合物及其合成方法、用途、组合物 |
| WO2016001851A1 (en) * | 2014-07-02 | 2016-01-07 | Dr. Reddy's Laboratories Limited | Preparation of ticagrelor |
| US9982061B2 (en) | 2014-10-01 | 2018-05-29 | Medimmune Limited | Antibodies to ticagrelor and methods of use |
| WO2016116942A1 (en) | 2015-01-20 | 2016-07-28 | Anlon Chemical Research Organization | Novel pharmaceutical compounds comprising ticagrelor with salts of aspirin |
| CN105985346B (zh) * | 2015-03-06 | 2019-10-18 | 苏州朗科生物技术股份有限公司 | 一种新的替格瑞洛化合物制备方法及其中间体化合物 |
| US9789087B2 (en) | 2015-08-03 | 2017-10-17 | Thomas Jefferson University | PAR4 inhibitor therapy for patients with PAR4 polymorphism |
| CN105237540B (zh) * | 2015-09-21 | 2017-10-03 | 南京正大天晴制药有限公司 | 一种替格瑞洛有关物质的制备方法、检测方法及用途 |
| WO2017118633A1 (en) | 2016-01-05 | 2017-07-13 | Amneal Pharmaceuticals Company Gmbh | Crystalline form of ticagrelor |
| TR201601835A2 (tr) | 2016-02-12 | 2017-08-21 | Ali Raif Ilac Sanayi Ve Ticaret Anonim Sirketi | Ti̇kagrelor i̇çeren formülasyonlar i̇çi̇n üreti̇m yöntemi̇ |
| US20170296666A1 (en) | 2016-04-18 | 2017-10-19 | Amneal Pharmaceuticals Company Gmbh | Stable Pharmaceutical Composition Of Amorphous Ticagrelor |
| CN107595789B (zh) | 2016-04-21 | 2021-01-15 | 阿斯利康(瑞典)有限公司 | 口腔崩解片 |
| SG11201901619WA (en) * | 2016-08-26 | 2019-03-28 | Mitsubishi Tanabe Pharma Corp | Bicyclic nitrogenated heterocyclic compound |
| US10905691B2 (en) | 2016-09-09 | 2021-02-02 | Université de Liège | Use of triazolo(4,5-d)pyrimidine derivatives for prevention and treatment of bacterial infection |
| EP3292867B1 (en) | 2016-09-09 | 2019-05-15 | Université de Liège | Triazolo(4,5-d)pyrimidine derivatives for use in the prevention and treatment of bacterial infection |
| CN107814772A (zh) * | 2017-11-24 | 2018-03-20 | 常州沃腾化工科技有限公司 | 4,6‑二氯‑5‑氨基‑2‑丙硫基嘧啶酯的精制方法 |
| EP3527571A1 (en) * | 2018-02-14 | 2019-08-21 | Université de Liège | Pyrimidine derivatives for prevention and treatment of bacterial infection |
| EP3829547A1 (en) | 2018-07-27 | 2021-06-09 | KRKA, d.d., Novo mesto | Pharmaceutical composition of ticagrelor |
| CN109761785A (zh) * | 2019-02-16 | 2019-05-17 | 安徽诺全药业有限公司 | 一种(1r，2r）-2-(3,4-二氟苯基)环丙烷羧酸的合成方法 |
| GB201910656D0 (en) * | 2019-07-25 | 2019-09-11 | Univ Liege | New use of triazolo(4,5-d)Pyrimidine deerivatives |
| EP3919497A1 (en) | 2020-06-04 | 2021-12-08 | Zaklady Farmaceutyczne Polpharma S.A. | Process for the preparation of ticagrelor |
| CN112876485A (zh) * | 2021-01-25 | 2021-06-01 | 郭丽伟 | 一种用于治疗子宫平滑肌高频率强直性收缩相关疾病的化合物 |
| EP4070658A1 (de) | 2021-04-06 | 2022-10-12 | BIORoxx GmbH | Verwendung von blutgerinnungshemmenden verbindungen als rodentizide |
| WO2023213198A1 (zh) * | 2022-05-04 | 2023-11-09 | 华东师范大学 | 芳香稠环化合物作为trek-1激活剂的用途、包含其的药物组合物、镇痛剂 |
Family Cites Families (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3106578A (en) | 1960-09-16 | 1963-10-08 | Smith Kline French Lab | Nu-phenethyl-2-phenylcyclopropylamine derivatives |
| SE329623B (pt) | 1967-06-08 | 1970-10-19 | C F Boehringer Soehne Gmbh | |
| DE1670265A1 (de) | 1967-08-25 | 1971-01-28 | Boehringer Mannheim Gmbh | 2-Amino-Adenosinderivate und Verfahren zu deren Herstellung |
| CH558137A (de) | 1971-05-17 | 1975-01-31 | Ciba Geigy Ag | Mittel zur beeinflussung des pflanzenwachstums. |
| US4016204A (en) * | 1975-10-31 | 1977-04-05 | Nelson Research & Development Company | Method of synthesis of trans-2-phenylcyclopropylamine |
| US4543255A (en) | 1984-05-10 | 1985-09-24 | Southern Research Institute | Carbocyclic analogs of purine 2'-deoxyribofuranosides |
| US4742064A (en) | 1985-09-10 | 1988-05-03 | Regents Of The University Of Minnesota | Antiviral carbocyclic analogs of xylofuranosylpurines |
| AT397801B (de) | 1988-01-20 | 1994-07-25 | Univ Minnesota | Didesoxydehydrocarbocyclische nucleoside und deren verwendung |
| EP0452360A4 (en) | 1988-12-12 | 1992-05-20 | Peter M. Palese | Methods and compositions for the prophylaxis and treatment of hepatitis b virus infections |
| US5110933A (en) | 1989-11-13 | 1992-05-05 | Board Of Regents Of Oklahoma State University | Salts of 3-azabicyclo[3.3.1]nonanes as antiarrhythmic agents, and precursors thereof |
| US5652366A (en) | 1990-09-25 | 1997-07-29 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | DI (1R)-(-)camphosulfonic acid) salt, preparation thereof and use thereof |
| AU665184B2 (en) | 1991-01-23 | 1995-12-21 | Gensia, Inc. | Adenosine kinase inhibitors |
| EP0508687B1 (en) | 1991-04-06 | 1995-09-13 | Astra Pharmaceuticals Limited | ATP analogues |
| EP0521463A3 (en) | 1991-07-04 | 1993-04-14 | Hoechst Aktiengesellschaft | Substituted cyclic cycloalkyltriols, process, intermediates for their preparation and their use as antiviral and antiparasitic agents |
| FI101150B (fi) | 1991-09-09 | 1998-04-30 | Sankyo Co | Menetelmä lääkeaineina käyttökelpoisten tetrahydrotienopyridiinin johd annaisten valmistamiseksi |
| US5817660A (en) | 1991-12-06 | 1998-10-06 | Hoechst Marion Roussel, Inc. | Trans cyclopentanyl purine analogs useful as immunosuppressants |
| US5338725A (en) | 1992-06-30 | 1994-08-16 | The Research Foundation Of The State University Of New York | Anti-aggregatory agents for platelets |
| IL108523A0 (en) | 1993-02-03 | 1994-05-30 | Gensia Inc | Pharmaceutical compositions containing adenosine kinase inhibitors for preventing or treating conditions involving inflammatory responses and pain |
| DE69406649T2 (de) | 1993-02-10 | 1998-03-05 | Astra Pharmaceuticals Ltd., Kings Langley, Hertfordshire | N-alkyl-2-substituierte atp-analoge |
| US5688774A (en) | 1993-07-13 | 1997-11-18 | The United States Of America As Represented By The Department Of Health And Human Services | A3 adenosine receptor agonists |
| US5620676A (en) | 1994-03-08 | 1997-04-15 | The United States Of America As Represented By The Department Of Health And Human Services | Biologically active ATP analogs |
| US5831099A (en) | 1995-03-10 | 1998-11-03 | The United States Of America As Represented By The Secretary Of The Army | Compounds of 1,5-disubstituted-3,7 diaza bicyclo 3.3.0! octanes and products containing the same |
| US5712258A (en) | 1995-03-23 | 1998-01-27 | The Trustees Of The University Of Pennsylvania | Inotropic ADP and ATP analogues and their pharmaceutical compositions |
| US6143749A (en) | 1995-06-07 | 2000-11-07 | Abbott Laboratories | Heterocyclic substituted cyclopentane compounds |
| JP4084415B2 (ja) | 1995-07-11 | 2008-04-30 | アストラゼネカ・アクチエボラーグ | 新しい血小板凝集抑制剤 |
| WO1997009330A1 (fr) | 1995-09-01 | 1997-03-13 | Hokuriku Seiyaku Co., Ltd. | Cristal d'hydrate et son procede de preparation |
| ATE270331T1 (de) | 1995-11-21 | 2004-07-15 | Euroscreen Sa | Rezeptor und dafür kodierendes nukleinsäuremolekül |
| US5948437A (en) | 1996-05-23 | 1999-09-07 | Zeneca Limited | Pharmaceutical compositions using thiazepine |
| ATE213245T1 (de) | 1996-12-20 | 2002-02-15 | Triazolo(4,5-d)pyrimidinyl-derivate und ihre verwendung als medikamente | |
| JPH10258654A (ja) | 1997-03-18 | 1998-09-29 | Delta Tsuuring:Kk | リクライニングシート |
| SE9702775D0 (sv) | 1997-07-22 | 1997-07-22 | Astra Pharma Prod | Novel compounds |
| SE9702772D0 (sv) * | 1997-07-22 | 1997-07-22 | Astra Pharma Prod | Novel compounds |
| SE9702773D0 (sv) | 1997-07-22 | 1997-07-22 | Astra Pharma Prod | Novel compounds |
| AR017014A1 (es) * | 1997-07-22 | 2001-08-22 | Astrazeneca Ab | Compuestos de triazolo [4,5-d]pirimidina, composiciones farmaceuticas, uso de los mismos para preparar medicamentos y procesos para la preparacionde dichos compuestos |
| SE9704709D0 (sv) | 1997-12-17 | 1997-12-17 | Astra Ab | Pharmaceutically active compounds |
| TWI229674B (en) | 1998-12-04 | 2005-03-21 | Astra Pharma Prod | Novel triazolo[4,5-d]pyrimidine compounds, pharmaceutical composition containing the same, their process for preparation and uses |
| DE60020010T2 (de) | 1999-06-21 | 2006-01-19 | Yamamoto Chemicals, Inc., Yao | Polymethinverbindungen, Verfahren zu deren Herstellung und deren Verwendung |
| SE9903759D0 (sv) | 1999-10-18 | 1999-10-18 | Astra Ab | Pharmaceutically active compounds |
| EP1775297A3 (en) | 1999-11-12 | 2008-12-03 | Biogen Idec MA Inc. | Adenosine receptor antagonists and methods of making and using the same |
| GB0013407D0 (en) | 2000-06-02 | 2000-07-26 | Astrazeneca Ab | Forms of a chemical compound |
| US7040429B2 (en) | 2001-10-10 | 2006-05-09 | Invacare Corporation | Wheelchair suspension |
| JP2005513099A (ja) | 2001-12-21 | 2005-05-12 | ファイザー・プロダクツ・インク | アジスロマイシンの直接的に圧縮可能な配合品 |
| TWI482772B (zh) | 2006-08-21 | 2015-05-01 | Astrazeneca Ab | 適合口服且包含三唑并[4,5-d]嘧啶衍生物之組合物 |
| US8563755B2 (en) | 2008-09-09 | 2013-10-22 | Astrazeneca Ab | Process for preparing [1S-[1-α, 2-α, 3-β(1S*,2R*) 5-β]]-3-[7-[2-(3,4-difluorophenyl)-cyclopropylamino]-5-(propylthio)-3H-1,2,3-triazolo [4,5-d] pyrimidin-3-yl]-5-(2-hydroxyethoxy) cyclopentane-1,2-diol and to its intermediates |
| US8859769B2 (en) | 2010-02-16 | 2014-10-14 | Actavis Group Ptc Ehf | Processes for preparing ticagrelor intermediate, 4,6-dichloro-5-nitro-2-(propylthio)pyrimidine |
| CN103003231A (zh) | 2010-06-30 | 2013-03-27 | 阿特维斯集团公司 | 制备苯基环丙基胺衍生物的新方法及其用于制备替卡格雷的用途 |
| RU2013133879A (ru) | 2010-12-20 | 2015-01-27 | Актавис Груп Птс Ехф | НОВЫЕ СПОСОБЫ ПОЛУЧЕНИЯ ТРИАЗОЛО[4, 5-d]ПИРИМИДИНА, ЕГО ПРОИЗВОДНЫЕ И ПРОМЕЖУТОЧНЫЕ СОЕДИНЕНИЯ |
| CA2832570A1 (en) | 2011-04-06 | 2012-10-11 | Teva Pharmaceutical Industries Ltd. | New intermediates and processes for preparing ticagrelor |
| CA2839057A1 (en) | 2011-06-15 | 2012-12-20 | Actavis Group Ptc Ehf | Improved process for preparing cyclopentylamine derivatives and intermediates thereof |
| MX2014006190A (es) | 2011-11-30 | 2014-07-10 | Actavis Group Ptc Ehf | Nueva forma cristalina de ticagrelor y proceso para la preparacion de la misma. |
| EP2834247A4 (en) | 2012-04-05 | 2016-03-30 | Reddys Lab Ltd Dr | PREPARATION OF TICAGRELOR |
| WO2014083139A1 (en) | 2012-11-29 | 2014-06-05 | Actavis Group Ptc Ehf | Novel amorphous form of ticagrelor |
| WO2014102830A1 (en) | 2012-12-31 | 2014-07-03 | Megafine Pharma (P) Ltd. | A process for preparation of ticagrelor and intermediates thereof |
| WO2014118808A2 (en) | 2013-02-04 | 2014-08-07 | Hetero Research Foundation | Ticagrelor solid dispersion |
| CN107573333B (zh) | 2013-04-10 | 2019-10-18 | 江苏恒瑞医药股份有限公司 | 替格瑞洛的中间体及其制备方法和替格瑞洛的制备方法 |
| WO2014195861A2 (en) | 2013-06-04 | 2014-12-11 | Dr. Reddy’S Laboratories Limited | Preparation of ticagrelor |
| WO2016001851A1 (en) | 2014-07-02 | 2016-01-07 | Dr. Reddy's Laboratories Limited | Preparation of ticagrelor |
| EP3250207A1 (en) | 2015-01-27 | 2017-12-06 | Astrazeneca AB | Method of treating or prevention of atherothrombotic events in patients with history of myocardial infarction |
-
1999
- 1999-11-19 TW TW088120241A patent/TWI229674B/zh active
- 1999-12-02 NZ NZ511778A patent/NZ511778A/en not_active IP Right Cessation
- 1999-12-02 ES ES03025535T patent/ES2366902T3/es not_active Expired - Lifetime
- 1999-12-02 DK DK03025535.0T patent/DK1386917T3/da active
- 1999-12-02 DK DK99963796T patent/DK1135391T3/da active
- 1999-12-02 CZ CZ20011962A patent/CZ295234B6/cs unknown
- 1999-12-02 US US09/508,195 patent/US6525060B1/en not_active Ceased
- 1999-12-02 AT AT03025535T patent/ATE513816T1/de active
- 1999-12-02 MY MYPI99005232A patent/MY121867A/en unknown
- 1999-12-02 ES ES99963796T patent/ES2216623T3/es not_active Expired - Lifetime
- 1999-12-02 AT AT03025536T patent/ATE418547T1/de active
- 1999-12-02 SI SI9931026T patent/SI1386921T1/sl unknown
- 1999-12-02 BR BRPI9915883A patent/BRPI9915883B8/pt not_active IP Right Cessation
- 1999-12-02 DE DE69915675A patent/DE69915675D1/de not_active Expired - Lifetime
- 1999-12-02 CZ CZ20080600A patent/CZ300373B6/cs not_active IP Right Cessation
- 1999-12-02 KR KR1020067015291A patent/KR100776484B1/ko active IP Right Grant
- 1999-12-02 DK DK03025536T patent/DK1386921T3/da active
- 1999-12-02 KR KR1020017006907A patent/KR100742924B1/ko active IP Right Review Request
- 1999-12-02 CZ CZ20041089A patent/CZ300280B6/cs not_active IP Right Cessation
- 1999-12-02 KR KR1020077014185A patent/KR100764417B1/ko active IP Right Grant
- 1999-12-02 SI SI9931059T patent/SI1386917T1/sl unknown
- 1999-12-02 SI SI9930550T patent/SI1135391T1/xx unknown
- 1999-12-02 EP EP03025535A patent/EP1386917B1/en not_active Expired - Lifetime
- 1999-12-02 ES ES03025536T patent/ES2318081T3/es not_active Expired - Lifetime
- 1999-12-02 EG EG154399A patent/EG24814A/xx active
- 1999-12-02 PT PT03025536T patent/PT1386921E/pt unknown
- 1999-12-02 EP EP03025537A patent/EP1386909A1/en not_active Withdrawn
- 1999-12-02 SK SK749-2001A patent/SK286007B6/sk not_active IP Right Cessation
- 1999-12-02 AU AU20165/00A patent/AU766618B2/en active Active
- 1999-12-02 KR KR1020067027016A patent/KR100822602B1/ko active IP Right Grant
- 1999-12-02 IL IL14323299A patent/IL143232A0/xx unknown
- 1999-12-02 DE DE201112100004 patent/DE122011100004I1/de active Pending
- 1999-12-02 CN CN99815926A patent/CN1128801C/zh not_active Ceased
- 1999-12-02 RU RU2001118284/04A patent/RU2317990C2/ru active Protection Beyond IP Right Term
- 1999-12-02 ID IDW00200101173A patent/ID29927A/id unknown
- 1999-12-02 TR TR2001/01567T patent/TR200101567T2/xx unknown
- 1999-12-02 AT AT99963796T patent/ATE261970T1/de active
- 1999-12-02 JP JP2000586728A patent/JP4202607B2/ja not_active Expired - Lifetime
- 1999-12-02 EP EP10183113A patent/EP2322513A3/en not_active Withdrawn
- 1999-12-02 PT PT99963796T patent/PT1135391E/pt unknown
- 1999-12-02 EP EP03025536A patent/EP1386921B1/en not_active Expired - Lifetime
- 1999-12-02 CA CA2351709A patent/CA2351709C/en not_active Expired - Lifetime
- 1999-12-02 US US14/976,977 patent/USRE46276E1/en not_active Expired - Lifetime
- 1999-12-02 HU HU0105081A patent/HU228589B1/hu active Protection Beyond IP Right Term
- 1999-12-02 DE DE69940171T patent/DE69940171D1/de not_active Expired - Lifetime
- 1999-12-02 EP EP99963796A patent/EP1135391B1/en not_active Expired - Lifetime
- 1999-12-02 WO PCT/SE1999/002256 patent/WO2000034283A1/en active Search and Examination
- 1999-12-02 DE DE69915675T patent/DE69915675T4/de not_active Expired - Lifetime
- 1999-12-02 PL PL348724A patent/PL201283B1/pl unknown
- 1999-12-03 AR ARP990106165A patent/AR023920A1/es not_active Application Discontinuation
- 1999-12-27 SA SA99200848A patent/SA99200848B1/ar unknown
-
2001
- 2001-05-17 IL IL143232A patent/IL143232A/en active Protection Beyond IP Right Term
- 2001-05-18 ZA ZA200104094A patent/ZA200104094B/en unknown
- 2001-06-01 NO NO20012725A patent/NO319806B1/no active Protection Beyond IP Right Term
-
2002
- 2002-02-19 HK HK04104367.3A patent/HK1061246A1/xx unknown
- 2002-02-19 HK HK02101198.6A patent/HK1039933B/zh unknown
- 2002-12-20 US US10/323,655 patent/US6974868B2/en not_active Expired - Lifetime
-
2004
- 2004-06-28 HK HK04104617.1A patent/HK1061684A1/xx unknown
-
2005
- 2005-06-06 IL IL169013A patent/IL169013A/en not_active IP Right Cessation
- 2005-09-21 US US11/230,493 patent/US7250419B2/en not_active Expired - Lifetime
-
2006
- 2006-10-18 JP JP2006283455A patent/JP2007084551A/ja not_active Ceased
-
2007
- 2007-01-10 AR ARP070100095A patent/AR058967A2/es active IP Right Grant
- 2007-02-28 US US11/711,838 patent/US20070265282A1/en not_active Abandoned
- 2007-06-14 IL IL183969A patent/IL183969A/en not_active IP Right Cessation
- 2007-09-11 RU RU2007133926/04A patent/RU2007133926A/ru not_active Application Discontinuation
-
2008
- 2008-05-08 US US12/149,771 patent/US20080214812A1/en not_active Abandoned
- 2008-05-23 JP JP2008135275A patent/JP5043749B2/ja not_active Expired - Lifetime
-
2009
- 2009-02-26 CY CY20091100225T patent/CY1110501T1/el unknown
- 2009-04-06 IL IL198040A patent/IL198040A/en not_active IP Right Cessation
- 2009-08-11 AR ARP090103085A patent/AR072756A2/es active IP Right Grant
- 2009-11-18 US US12/591,395 patent/US20100069408A1/en not_active Abandoned
-
2010
- 2010-09-08 JP JP2010200486A patent/JP5415383B2/ja not_active Expired - Lifetime
- 2010-12-30 IL IL210398A patent/IL210398A0/en unknown
-
2011
- 2011-05-18 CY CY2011005C patent/CY2011005I2/el unknown
- 2011-05-23 FR FR11C0016C patent/FR11C0016I2/fr active Active
- 2011-05-23 NO NO2011007C patent/NO2011007I2/no unknown
- 2011-05-25 LT LTPA2011004C patent/LTC1135391I2/lt unknown
- 2011-05-31 LU LU91819C patent/LU91819I2/fr unknown
- 2011-07-21 US US13/137,125 patent/US20120165348A1/en not_active Abandoned
- 2011-08-17 CY CY20111100786T patent/CY1111759T1/el unknown
-
2012
- 2012-03-19 US US13/423,848 patent/US20130072503A1/en not_active Abandoned
- 2012-05-25 RU RU2012121883/04A patent/RU2593201C2/ru active
- 2012-10-31 US US13/665,241 patent/US20130109702A1/en not_active Abandoned
-
2013
- 2013-09-05 HU HUS1300048C patent/HUS1300048I1/hu unknown
- 2013-10-31 US US14/068,942 patent/US20140296258A1/en not_active Abandoned
-
2014
- 2014-06-20 US US14/310,315 patent/US20150152111A1/en not_active Abandoned
-
2022
- 2022-03-23 NO NO2022007C patent/NO2022007I1/no unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA200104094B (en) | Novel triazolo(4,5-d)pyrimidine compounds. | |
| EP0996620B1 (en) | Novel compounds | |
| WO1999005144A1 (en) | Novel compounds | |
| EP1232156A1 (en) | Novel 1,2,3]-triazolo 4,5-d]pyrimidine compounds | |
| US7034032B2 (en) | Cyclopentan-2-ol-1-yl-[1,2,3]triazolo[4,5-D]pyrimidine compounds | |
| MXPA01005531A (en) | Novel triazolo(4,5-d)pyrimidine compounds |